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Abstract
Tat protein, released by HIV-infected cells, has a battery of important biological effects leading to distinct AIDS-associated
pathologies. Cell surface heparan sulfate protoglycans (HSPGs) have been accepted as endogenous Tat receptors, and the
Tat basic domain has been identified as the heparin binding site. However, findings that deletion or substitution of the basic
domain inhibits but does not completely eliminate Tat–heparin interactions suggest that the basic domain is not the sole
Tat heparin binding site. In the current study, an approach integrating computational modeling, mutagenesis, biophysical
and cell-based assays was used to elucidate a novel, high affinity heparin-binding site: a Lys12, Lys41, Arg78 (KKR) spatial
domain. This domain was also found to facilitate Tat-driven b1 integrin activation, producing subsequent SLK cell adhesion
in an HSPG-dependent manner, but was not involved in Tat internalization. The identification of this new heparin binding
site may foster further insight into the nature of Tat-heparin interactions and subsequent biological functions, facilitating
the rational design of new therapeutics against Tat-mediated pathological events.
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Introduction
The transactivating factor of the HIV-1 virus (Tat), released
from human immunodeficiency virus type 1 (HIV-1) infected cells,
has been pointed towards a variety of important biological
functions related to the distinct AIDS-associated pathologies in
AIDS patients, including neuropathies[1], and immune suppres-
sion[2,3] and increased tumorigenesis in AIDS patients[3].
Tat is a polypeptide of 86–102 amino acids depending on the
viral strain[4]. Amino acids 1–72 are endowed with full
transactivating activity[5], present within a basic domain (amino
acids 48–57) constituted by a stretch of repeated Arg and Lys
residues critical for a number of biological functions, while amino
acids 72–86 of the carboxy terminal region contain an Arg-Gly-
Asp (RGD) motif responsible for binding to integrin receptors and
subsequent cell adhesion[4,6].
Tat-driven activities depend precisely on its interaction with
cell surface heparan sulfate (HS) and heparin through their
negatively charged sulfate groups[7]. The basic domain has long
been recognized as the sole contributor mediating this interaction
via its heparin binding properties[8,9,10,11]. However, recent
limited studies have challenged this notion with the demonstra-
tion that deletion or substitution of the basic domain really
affects, but does not completely eliminate Tat-heparin interac-
tions[9]. This led us to hypothesize that other heparin binding
sites might exist.
Toward this end, we sought to identify novel Tat heparin
binding sites using the molecular simulation for appreciable
prediction, combined with the surface plasmon resonance (SPR)-
based competitive inhibition assay and cell-based functional
evaluation with the introduction of several relevant targeted
mutant Tat proteins. Encouragingly, a triad of basic residues—
Lys12, Lys41 and Arg78 (KKR)—that are spatially enclosed
rather than sequentially oriented, was thus identified as a hereto
unrecognized high-affinity heparin binding site which help
facilitate Tat-driven b1 integrin activation and subsequent
adhesion in an heparan sulfate protoglycan (HSPG)-dependent
manner. Clearly, our findings will facilitate a crucial touch on a
precise understanding of the comprehensive roles of Tat as well as
aid in design of new therapeutic agents.
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Molecular simulation predicts that Lys12, Lys41, and
Arg78 comprise a novel Tat heparin binding site
Computational modeling was first employed with the aim of
identifying the potential heparin binding sites. Here, the homology
model of Tat protein (Tat-III) constructed on the basis of NMR
data was utilized as the target structure, and several heparin
oligosaccharides including di-, tetra-, hexa-, and octa-saccharides
were selected as docking probes. In the disaccharide heparin
model, heparin was noted to preferentially interact with a triad of
basic residues (Lys12, Lys41 and Arg78 (KKR); Figure 1,
highlighted in green). For better resolution, a closeup view of the
binding interface was developed. In the zoomed view, It was
evident that the 2-O-sulfate of the glucuronic acid ring was in close
proximity to Lys41 in Nf, which itself is engaged in two tight salt
bridges (2.84 and 2.88 A ˚, respectively). Nf atom of Lys12, in a like
manner, was involved in two hydrogen bonds, established with the
3-O (3.30 A ˚) and 2-O (2.74 A ˚) of the glucuronic acid ring.
Another strong salt bridge (2.77 A ˚) was observed between the 5-
carboxylate group and Ng of Arg78. The binding free energy of
the disaccharide was further calculated as 28.84 kcal/mol,
indicative of the nanomolar or even lower level of the binding
affinity of Tat-III for heparin.
Of particular note, among the 20 distinct docking runs, though
a few predicted poses were docked at the basic domain, it however
generated much higher estimated binding free energies. These
finding from an alternative view suggested that the KKR triad
may yield a higher affinity for heparin than that of the basic
domain.
Modeling of interactions with tetra-, hexa- and octa-saccharides
revealed similar results; the positively charged KKR triad plays an
important role in the molecular recognition of heparin probes
producing a highly conserved interaction with Tat-III. It should be
noted that the oligosaccharide chain begins to stretch toward the
basic domain (yellow for comparison) as the probe length
increases. As the length increases to a tetramer, a delicate
interaction with residue Arg49 of the basic domain is established;
the hexamer follows the same path and approaches residue Arg52;
when the heparin oligosaccharide reaches octameric size, it enlists
residue Gln54. Their binding free energies were calculated as
29.21, 211.53 and 212.30 kcal/mol, respectively. Heparin
ideally, if long enough, is proposed to encompass both the KKR
region and fully extend to the whole basic domain; and Arg49
might serve as a ‘knot/link’ between the two binding sites.
Surface plasmon resonance confirms that the KKR
domain is a spatially enclosed Tat heparin binding site
To characterize the Tat KKR motif engaged with heparin, a
series of Tat mutants were expressed in E. coli as GST fusion
proteins, purified from the bacterial lysates by glutathione-agarose
affinity chromatography and checked by SDS-PAGE (Figure 2A).
The identification of mutant products was further carried out by
MS-MS spectral analysis (Supplemental Text S1 and Figure S1,
S2, S3, S4). In addition, the similarity of secondary structure of the
mutated products to the native Tat protein was predicted using a
position-specific scoring method [12](data not shown).
First, the EC50 binding capacity was evaluated. For this, a series
of GST-Tat solutions with a range of concentrations (0.25, 0.5, 1,
2, and 4 mM) were injected over a heparin-immobilized sensor
chip surface. RUmax values were generated using BIAcore
evaluation 3.1 software, yielding an EC50 value of 1.5 mM
(Figure 2B); this value was used as a reference for subsequent
experiments.
We next investigated whether KKR is a heparin binding site, as
predicted. A series of comparative studies were performed using all
relevant mutants. We found that GST-Tat binding to heparin
involves multi-phasic binding (Figure 2D)[13], indicating the
existence of more than one heparin binding site. Notably,
mutation of the basic domain still produced monophasic binding,
further supporting the notion that another binding site for heparin
Figure 1. Computational docking model of HIV-Tat with heparin-derived fragments. Predicted interaction modes between HIV-Tat and
heparin-derived fragments, including di- (A, B and C), tetra- (D), hexa- (E), and octa-saccharide (F) were indicated. Tat was represented in surface and
oligosaccharides in stick. The Tat surface was colored by electrostatic potential in A.I nB–F, it was colored in white, with the KKR region and basic
domain highlighted in green and yellow, respectively. A close-up view of the binding interface between the di-saccharide and the KKR (Lys12, Lys41
and Arg78) region was shown in C, where the surface was set to transparent, the protein main chain was shown in ‘worm’ representation, and
hydrogen-bonds are represented by yellow dotted lines.
doi:10.1371/journal.pone.0002662.g001
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PLoS ONE | www.plosone.org 2 July 2008 | Volume 3 | Issue 7 | e2662Figure 2. Identification of the Tat Lys12, Lys41, Arg78 (KKR) domain as a new heparin binding site. A, SDS-PAGE analysis of the
purification of GST-Tat and series Tat mutants . a, 1, Marker; 2, GST-Tat; 3, GST-Tat(G48-R57)A; 4, GST-TatK(12,41)A/R78A; 5, GST-Tat(G48-R57)A/K(12,41)A/R78A.b ,1 ,
Marker; 2, GST; 3, GST-TatK12A; 4, GST-TatK41A; 5, GST-TatR78A; 6, GST-TatK(12,41)A; 7, GST-TatK12A/R78A; 8, GST-TatK41A/R78A; 9, GST-TatR78A/G79A/D80A.B ,
Binding activities of GST-Tat to heparin immobilized on a CM5 sensor chip. Varying concentrations of GST-Tat (0.25, 0.5, 1, 2, 4 mM) were injected over
the heparin-immobilized sensor chip surface, and binding of GST-Tat to heparin was recorded as RU. C, Interaction of GST-Tat and its mutants with
biotinylated heparin immobilized on a CM5 sensor chip. GST-Tat or the appropriate mutants (1.5 mM) were injected over the heparin-immobilized
sensor chip. The binding RU was recorded as binding potency. D, Scatchard plot analysis of GST-Tat and GST-Tat(G48-R57)A with immobilized heparin.
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of Lys12, Lys41, Arg78 with alanine [GST-TatK(12,41)A/R78A]
displayed a markedly decreased binding potency for heparin when
compared to wild-type GST-Tat (Figure 2C). Moreover, double-
mutant GST-Tat(G48-R57)A/K(12,41)A/R78A led to the complete
abolishment of Tat-heparin interactions. These findings substan-
tiate our hypothesis that Tat indeed possesses another heparin
binding site, identified herein as the KKR region.
We next clarified the contribution of the three basic residues.
Single, double or triple mutations of the KKR region were
constructed and their binding affinities for immobilized heparin
were recorded and compared using the SPR assay. KD values were
calculated using BIAcore evaluation 3.1 software. Mutation of a
single residue (GST-TatK12A, GST-TatK41A, or GST-TatR78A) led
to only a partial loss of heparin binding affinity (KD 0.275 nM,
0.155 nM or 0.0241 nM, respectively), with the Arg78 mutation
(GST-TatR78A) influencing binding affinity the least. Moreover,
mutation of any two KKR residues (GST-TatK(12,41)A, GST-
TatK12A/R78A, GST-TatK41A/R78A) led to a significant loss of
binding affinity with correspondingly decreased KD values
(1.42 nM, 0.249 nM and 0.154 nM), with Lys12, Lys41 mutation
(GST-TatK(12,41)A) affecting binding the most. Most significantly,
concurrent mutation of all three residues produced a dramatic
drop in heparin binding affinity, with a resultant KD value of
32.6 nM. This series of experiments collectively indicated that
Lys12, Lys41 and Arg78 cooperate to profoundly impact heparin-
binding (Table 1).
The KKR spatial triad binds specifically to heparin in a
high affinity manner
We next sought to delineate the nature of KKR-associated
heparin binding in an attempt to define the intrinsic properties of
this newly discovered binding site. We studied binding affinity
(KD), a key feature of the binding mode. A series of concentr-
ations of GST-Tat, GST-Tat(G48-R57)A and GST-TatK (12,41)A/R78A
were injected over the heparin-immobilized sensor chip surface
(Figure 3A). We found that GST-Tat is capable of binding to
heparin (KD=1.17 pM) (Table 1). Mutation of the basic domain
(leaving the KKR domain intact and thus solely responsible for the
strength of the Tat KKR-heparin interaction) led to a decrease in
binding affinity (KD=5.31 pM). This value represents nearly a five-
fold reduction in affinity as compared to wild-type GST-Tat.
Mutation of the KKR region, however, caused a remarkable
decrease in GST-Tat-heparin binding (KD=32.6 nM), represent-
ing the KD value of the basic domain in isolation. This KD
represents a 10,000 fold decrease in binding affinity compared with
that of wild-type GST-Tat (Table 1). Based on this comparison, we
conclude that the KKR spatial region dominates Tat-heparin
binding in comparison to the basic domain.
We next conducted a series of experiments evaluating heparin-
mediated competitive inhibition of Tat-heparin binding for
further confirmation. Wild-type GST-Tat or the appropriate Tat
mutants (1.5 mM) was injected over a heparin-immobilized chip
in the presence of varying concentrations of heparin as a
competitive inhibitor. Free heparin was able to inhibit the
binding of either GST-Tat or the corresponding mutant to
immobilized heparin in a dose-dependent manner (Figure 3B).
Notably, mutation of the basic domain (GST-Tat(G48-R57)A)
produced an IC50 value (0.659 mg/ml) comparable to that of
GST-Tat (0.717 mg/ml), while mutation of the KKR region
(GST-TatK (12,41)A/R78A)y i e l d e da nI C 50 value of 1.574 mg/ml,
almost twice that of GST-Tat. These data further support the
notion that the KKR spatial domain contributes dramatically to
heparin binding, and represents an extremely high-affinity
heparin binding site.
We then characterized KKR binding specificity, another
important component of the binding mode, via introduction of a
series of soluble glycosaminoglycans (GAGs) using competitive
inhibition assay. Both heparin and HS were able to compete for
KKR binding to heparin, yielding IC50 values of 0.717 mg/ml and
20.677 mg/ml respectively. By contrast, other GAGs including
CSA, CSC and HA, even at concentrations up to 250 mg/ml,
showed little or no inhibition of this interaction (Figure 3C). These
findings support the high specificity of the KKR region for
heparin.
Thus, the newly identified KKR region, distinct from the well-
recognized linearly contiguous basic domain, serves as both an
extremely high-affinity and highly specific binding motif for
heparin.
The KKR spatial region is not involved in Tat-driven
internalization
It is well-known that Tat-regulated function mostly precisely
depends on the association of Tat with cell surface heparin sulfate/
heparin via the negatively charged sulfate group. Of note, Tat-
driven internalization indispensably counts on Tat’s heparin-
binding properties[10]. We thus examined whether the KKR
region is involved in this critical event. For this purpose, SLK cells
were preferentially adopted. As shown in Figure 4A, GST-Tat is
capable of internalizing into SLK cells, reaching maximal
intracellular concentration within 24 h, and consistently, the
mutation of the basic domain (GST-Tat(G48-R57)A) is expected to
cause a complete loss in Tat internalization[10], again indicating
the dominance of the basic domain in this setting. The substitution
of KKR region with alanine (GST-TatK(12,41)A/R78A), however,
failed to affect internalization at all. This helps exclude the
involvement of the KKR spatial domain in Tat protein
internalization.
Table 1. The binding affinity parameters of GST-Tat and its
mutants to heparin.
Analyte KA(1/M) KD (M)
GST-Tat 8.56E+11 1.17E212
GST-Tat(G48-R57)A 1.88E+11 5.31E212
GST-TatK (12, 41)A/R78A 3.07E+07 3.26E208
GST-TatK12A 3.64E+09 2.75E210
GST- TatK41A 6.45E+09 1.55E210
GST- TatR78A 4.15E+10 2.41E211
GST- TatK(12, 41)A 7.05E+08 1.42E209
GST-TatK12A/R78A 4.02E+09 2.49E210
GST- TatK41A/R78A 6.51E+09 1.54E210
KA: equilibrium association constant; KD: equilibrium dissociation constant. Data
shown are typical from three independent experiments with similar results.
doi:10.1371/journal.pone.0002662.t001
Series concentrations of GST-Tat or GST-Tat(G48-R57)A was injected over the heparin-immobilized sensor chip surface. The binding potency/
concentration (RU/C) was plotted versus RU. (a) and (b) stand for Scatchard plots for GST-Tat, GST-Tat(G48-R57)A respectively.
doi:10.1371/journal.pone.0002662.g002
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PLoS ONE | www.plosone.org 4 July 2008 | Volume 3 | Issue 7 | e2662Figure3.CharacterizationoftheintrinsicpropertiesoftheTatKKRheparinbindingdomain. A, Sensorgrams of GST-Tat and its mutants with
immobilized heparin. Serial concentrations of GST-Tat and its mutants were injected over the heparin-immobilized sensor chip surface. The real time
binding were recorded as response (RU) versus time. (a), (b) and (c) represent sensorgrams for GST-Tat, GST-Tat(G48-R57)A, and GST-TatK (12,41)A/R78A
respectively. B, Heparin competitively inhibits binding of GST-Tat and its mutants with immobilized heparin. GST-Tat (a), GST-Tat(G48-R57)A (b)
and GST-TatK (12,41)A/R78A (c) (1.5 mM) alone or in the presence of serial concentrations of heparin were injected over an heparin immobilized
chip surface, respectively. The responses (in RU) were plotted versus the concentration of heparin. Insets, overlay of sensograms showing the
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cell adhesion via b1 integrin activation in a cell surface
HSPG-dependent manner
The KKR spatial region facilitates Tat-mediated SLK cell
adhesion. In addition to the Tat-driven internalization, Tat also
mimics the effect of extracellular matrix molecules and favors cell
adhesion via the amino acid sequence RGD[4,6]. We thus reasoned
that KKR might involve the Tat-mediated RGD-executed cell
adhesion. For this, we again selected SLK cells as a surrogate to
examine the impactofKKR on celladhesion.Replacementof KKR
with alanine (GST-TatK(12,41)A/R78A) induced a partial but
incomplete abolishment of SLK cell adhesion compared with that
ofGST-Tat(Figure4B),suggestingthisnew heparinbinding siteisat
least partially involved in Tat-mediated cell adhesion. In
comparison, substituting RGD with alanine (GST-TatR78A/G79A/
D80A) resulted in a complete defect in cell adhesion. These findings
together underscore the predominant role of RGD on one hand and
meanwhile revealing a complementary action of KKR in Tat-driven
cellular adhesion. Furthermore, mutation ofthe basic domain(GST-
Tat(G48-R57)A) generated a similar profile, as did double mutation of
both KKR and the basic domain (GST-Tat(G48-R57)A/K(12,41)A/R78A)
which yields amorepotentreduction incelladhesioncompared with
KKR-mutated Tat. These findings further support the concept that
the KKR spatial triad is an essential, but incomplete, contributor to
Tat-mediated cell adhesion.
The KKR region triggers b1 integrin activation in SLK
cells. Since Tat promotes SLK cell adhesion through binding
a5b1 integrins[6,14], we next evaluated whether the KKR drives
this activation. Activation of b1 integrin was recorded in GST-
Tat-treated SLK cells, as evident from the typical dot-like staining
observed in peripheral ruffles and cell edges (Figure 4D)[15,16,17].
In contrast, an appreciable loss of dot-like staining was observed in
SLK cells after treatment with GST-TatK(12,41)A/R78A. GST-
Tat(G48-R57)A treatment resulted in conserved diffuse b1 integrin
staining, while GST-Tat(G48-R57)A/K(12,41)A/R78A produced less b1
integrin activation. However, the activated b1 integrin induced by
GST-TatR78A/G79A/D80A couldn’t be detected due to its disability
on cell adhesion (data not shown). All these findings are
concordant with the results obtained in the cell adhesion assay,
which is the consequence of b1 integrin activation.
The KKR region executes its function in a cell surface
HSPG-dependent manner. To address whether cell surface
HSPG acts as a chaperone for KKR-facilitated cell adhesion
events in the context of its heparin binding properties, we
performed a series of competitive inhibition assays designed to test
its effects on cell adhesion. This was accomplished either by
introducing soluble heparin or a specific monoclonal antibody
raised against cell surface HS (MAB2040). GST-Tat-induced SLK
cell adhesion was inhibited by heparin at concentrations of
200 mg/ml (Figure 4C). Furthermore, heparin, at the same
concentration, competitively suppressed SLK cell adhesion
induced by KKR-dominant but basic domain-substituted Tat
[GST-Tat(G48-R57)A]. Consistently, MAB2040 also significantly
blocked SLK cell adhesion facilitated by KKR-dominant but basic
domain-substituted Tat [GST-Tat(G48-R57)A], indicating that
KKR-mediated adhesion is heparin-dependent.
We subsequently examined the effects of heparin on KKR-
facilitated b1 integrin activation. Here, pretreatment with heparin
at a concentration of 1 mg/ml resulted in a competitive loss of b1
integrin staining induced by KKR-dominant but basic domain-
substituted Tat [GST-Tat(G48-R57)A] (Figure 4D). Together, these
results clearly suggest that the KKR region executes its biological
function in a cell surface HSPG-dependent manner secondary to
its heparin binding properties.
Discussion
Rusnati et al.[9] previously recognized that the neutralization of
six arginine residues within the basic domain was not sufficient to
abolish the heparin binding capacity of Tat. They suggested that
the remaining lysine residues in the basic region and/or other
basic amino acids scattered on the surface of the Tat protein
contributed to the residual heparin binding capacity they
observed. Since that time, however, limited studies have touched
this inconsistency in existing models of Tat-heparin interactions.
With the availability of NMR-based Tat structure models together
with progress that has been made in molecular simulations as well
as the SPR technique, we were able to challenge the existing
dogma and provide a direct evidence that it is a triad KKR region
that functions as the crucial determinant of Tat-heparin
interaction in addition to the basic domain.
In the present study, a homology model of Tat-III constructed
using its NMR structure docked with heparin oligos probes
provided a promising candidate motif for heparin binding in
addition to the well-recognized basic domain. Further analysis of
the free energy of heparin-Tat-III interactions and detailed
assessment of their atomic associations, coupled with flexible
molecular docking schemes substantially predicted the confluence
of a triad of basic residues Lys12, Lys41, Arg78 (designated as
KKR triad) into a previously unrecognized binding site for
heparin.
The SPR biosensor assay is an accurate and powerful method of
dig the molecule-molecule interactions[18,19,20], while mutation
studies provide a wealth of information about biological functions.
By combining these two approaches, we successfully defined the
intrinsic properties of the KKR domain and characterized its
functional importance. Using the SPR assay, a multiphasic
binding mode between Tat and heparin was observed. With
mutation of the basic domain, a monophasic binding series
became evident. A complete loss of binding capacity for heparin
was then noted with double mutation of both KKR and the basic
domain. These findings collectively support the idea that the Tat
protein offers two binding sites for heparin: the well-recognized
basic domain, and the newly identified KKR region. This model is
congruent with our simulation-based predictions. Notably, the
observation that mutants with either a single or a double
substitution of KKR residues does not dramatically affect heparin
binding affinity, while a triple mutation significantly did, highlights
the importance of all residues in this triad for functionality.
Delineation of the intrinsic properties of the newly identified
binding site is important since it assists in unraveling the nature of
the domain’s interaction with heparin. By kinetics analysis, the
dissociation constant (KD value) was calculated as 5.31 pM, which
represents an extremely high-affinity binding interaction (,10,000
times that of the basic domain). The disparity in binding affinity
between the KKR and the basic domain, in principle, should allow
binding of GST-Tat and its mutants to immobilized heparin in the presence of increasing concentrations of heparin. C, The inhibitory action
of different glycosaminoglycans on GST-Tat(G48-R57)A-heparin interaction. GST-Tat(G48-R57)A (1.5 mM) was preincubated with increasing
concentrations of free HS, CSA, CSC, and HA (7.8, 15.6, 31.3, 62.5, 125, 250 mg/ml), respectively, and injected over a biotinylated heparin
surface.
doi:10.1371/journal.pone.0002662.g003
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demonstrate that heparin can specifically recognize the KKR
region when the disaccharide probe was used. As the length of the
oligosaccharide increases, the oligomer stretches toward and along
the basic domain: it begins to form interactions with Arg49 when
the tetramer probe was used, approaches Arg52 as the probe size
increases to 6 sugar unit, and reaches Gln54 as the sugar length is
8. Ideally, heparin at its typical length would simultaneously bind
to both KKR and the whole basic domain, with residue Arg49
serving as the ‘knot/link’ between the two regions.
Another important feature shaped by the KKR domain is its
specificity for heparin, as is evident from the observation that only
heparin/HS but not other GAGs including CSA, CSC and HA
were able to produce a dose-response-based competitive inhibitory
effect on Tat-heparin interactions. Because sugar-protein interac-
tions are predominately dependent on saccharide composition and
the extent and distribution of sulfation of the sugar back-
bone[21,22], the high affinity of Tat for heparin may be a
product of both its defined sulfate groups and specific saccharide
composition. However, though heparin and HS are comprised of
same saccharide composition, HS still displays differences from
heparin in binding affinity for KKR triad, which clearly points to
the importance of the extent of sulfation of sugar chains in
specificity of sugar-protein recognition.
Current views hold that heparin binding sites are commonly
recognized on the external surface of proteins and correspond to
shallow pockets of positive charge that are often linearly
contiguous or, alternatively, may be distant in sequence yet closely
spatially orientated when the protein assumes its native tertiary
structure[23,24,25]. Unlike the linearly contiguous sequence of the
basic domain, the KKR residues, although distant in sequence, are
brought into close spatial proximity via Tat conformational
folding. This intrinsic difference might endow the KKR with a
contribution to Tat function distinct from that of the basic domain.
Indeed, the fact that the KKR is only capable of facilitating Tat-
driven activation of b1 integrin and subsequent cell adhesion
(similar to the basic domain), but fails to produce intracellular
internalization (unlike the basic domain) favors such a notion. Of
course, the delicate nature of heparin-KKR interactions will
require further elucidation.
Regarding integrin activation and subsequent adhesion, one
important issue merits further addressed: the KKR triad matches
quite well in a similar pattern with RGD-driven events that
depend on its engagement with cell surface HS[4]. However, a
complete loss of integrin activation and subsequent cell adhesion
via the replacement of the RGD region, but only a partial loss
observed with KKR substitution, convincingly support the concept
that the KKR is an essential but not dominant component in
mediating cell adhesion events as RGD does. This triad,
alternatively resembling the basic domain, cooperates with the
RGD motif in integrin activation and subsequent adhesion.
In sum, we herein show for the first time that a triad of Lys12,
Lys41, Arg78 domain is a novel, high-affinity, spatially enclosed
heparin binding site on Tat, which we have further defined as
important in facilitating Tat-driven integrin activation and
subsequent cell adhesion in an HSPG-dependent manner. Of
note, this newly identified heparin binding site functions similarly
to the basic domain as a participator in Tat-triggered cell adhesion
on one hand, but behaves quite differently from the basic domain
in the internalization process. Particularly, the findings that in
addition to the commonly accepted basic domain, the KKR
region is an extremely high affinity heparin binding site appeal a
careful consideration when interpreting Tat-driven adhesion
events. Further characterization of functional synergy of KKR-
mediated Tat-heparin interactions will add a crucial component of
understanding AIDS-associated pathological in particular and
Tat-driven battery of biological events in general. Also, challeng-
ing efforts towards the interest in the KKR-targeted rational
designing for novel therapeutics are further needed.
Materials and Methods
Reagents
Heparin, HS, chondroitin sulfates A (CSA) and C (CSC),
hyaluronic acid (HA) and Cy3-conjugated sheep anti-mouse IgG
were obtained from Sigma (St. Louis, MO). Anti-GST antibody
(sc-459) was purchased from Santa Cruz Biotechnology, Inc.
(Santa Cruz, CA). Monoclonal antibodies to activated-integrin b1
(12G10) and HS (MAB2040) were obtained from Chemicon
International, Inc. (Temecula, CA). FITC-conjugated goat anti-
rabbit IgG was purchased from Jackson Immunoresearch
Laboratory Inc. (West Grove, PA).
Cell culture
SLK cells (derived from an endothelial-origin Kaposi’s sarcoma)
were kindly provided by the NIH AIDS Research division. The
cells were maintained in RPMI1640 medium supplemented with
10% heat-inactivated fetal calf serum (FCS, Gibco Gaithhersburg,
MD), 2 mM L-glutamine, 100 IU/ml penicillin, and 100 mg/ml
streptomycin at 37uC in a humidified incubator with 5% CO2.
Computational docking modeling
The amino acid sequence of human T-lymphotropic virus 3
(Tat-III protein) was retrieved from the appropriate NCBI
Pubmed entry (http://www.ncbi.nlm.nih.gov/) (GI: 328765) for
phylogenetic analyses. A BLASTP (http://www.ncbi.nlm.nih.
gov/blast) search of the sequence revealed a highly homologous
protein, Tat-I (83/86 aa, 96%identity), of which 11 NMR solution
structures have been determined (PDB entry 1JFW)[26]. There-
fore, the structure of Tat-I was used as the template to create a 3D
model of Tat-III using the MODELLER program implemented in
INSIGHT II(Insight II. UserGuide, MSI Inc., San Diego, USA,
2000) [27]. Ten models were generated, and these 3D structures
were optimized with a conjugate gradient minimization scheme
followed by a restrained simulated annealing molecular dynamics
simulation. The model with the lowest value of the objective
function was selected as the most representative Tat-III model for
Figure 4. Effects of the KKR domain on Tat-mediated internalization and adhesion in SLK cells. A, Internalization of extracellular Tat
fusion protein and its mutant derivatives in SLK cells. Cells were treated with GST-Tat or its mutants (1.6 mg/ml). After 24 h, cells were extensively
washed, fixed, and internalized fusion protein was stained with monoclonal anti-GST antibody [1:100], followed by FITC-conjugated goat anti-rabbit
IgG secondary antibody [1:500] (green) and detected with immunofluorescence confocal microscopy. (a)GST, (b)GST-Tat, (c)GST-Tat(G48-R57)A,( d) GST-
TatK (12,41)A/R78A. B, Effect of immobilized Tat and its mutants on SLK cell adhesion (x ¯6s, n=3), ##p,0.01 vs GST; **p,0.01 vs. GST-Tat. C, Effect of
soluble heparin and blockade of cell surface heparan sulfate on GST-Tat(G48-R57)A adhesion in SLK cells (x ¯6s, n=3), ##p,0.01 vs GST; **p,0.01 vs.
GST-Tat(G48-R57)A. D, Effect of KKR domain mutation on b1-integrin clustering in SLK cells. Activated b1 integrin was detected using monoclonal
antibody 12G10, and probed using Cy3-conjugated sheep anti-mouse IgG (red). (a) GST, (b) GST-Tat, (c) GST-Tat(G48-R57)A,( d) GST-TatK (12,41)A/R78A (e)
GST-Tat(G48-R57)A/K(12,41)A/R78A,( f) GST-Tat(G48-R57)A/heparin.
doi:10.1371/journal.pone.0002662.g004
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tetrasaccharide and octasaccharide analogues were also built in
INSIGHT II based on its NMR solution structure (PDB entry
1HPN)[28].
Structure-based analysis of our homology model of Tat-III was
performed in order to search for novel heparin binding sites by
using the advanced docking program AUTODOCK4.0
[29,30,31]. The docking operation algorithm was performed in a
consistent manner. In the first step, a large grid box encompassing
the entire Tat-III structure, with 12061206120 points, was
generated to take all possible heparin binding sites into account.
The spacing parameter was set to 0.375 A ˚ and affinity and
electrostatic potential maps were calculated for each type of atom
present in the heparin structure. Then, the Lamarckian genetic
algorithm (LGA) was applied to account for protein-ligand
interactions using a newly revised scoring function that includes
the terms vdw (Van der Waals), hydrogen bond, desolvation
energy, torsional free energy and unbound system energy[29]. The
step size was set to 0.2 A ˚ for translation and 5u for orientation and
torsion. The number of generations, energy evaluations, and
docking runs were set to 500,000, 2,500,000 and 20, respectively.
Finally, the evaluation with the lowest binding energy was used to
analyze ligand pose and the interaction model of heparin/Tat-III
was produced using the LIGPLOT program based on the docked
complex structure[32].
Preparation of Tat and its mutants
Plasmid pGEX-2T (Amersham Pharmacia, Uppsala, Sweden)
and pGST-Tat were kindly provided by Profs. M Giacca and M
Prestai (International Centre for Genetic Engineering and
Biotechnology, Trieste, Italy). Tat mutants were constructed using
site-directed mutagenesis, yielding series of GST-Tat mutants
(Table 2).
The plasmids expressing different Tat mutants were obtained by
cloning a PCR-amplified fragment into the BamHI and EcoRI sites
of the vector pGEX-2T. Templates for amplification were plasmid
pGEX2T-Tat-derived. All the constructs were verified by DNA
sequencing.RecombinantwildtypeHIV-1TatandthedifferentTat
mutants were expressed in Escherichia coli as glutathione S-
transferase (GST) fusion proteins and purified to homogeneity from
bacterial lysates by glutathione-sepharose affinity chromatography
(Amersham Pharmacia Biotech) according to the manufacturer’s
instructions. The purity and integrity of the protein product were
routinely checked by SDS-polyacrylamide gel electrophoresis and
0.25% Coomassie brilliant blue R-250 staining. The purified
proteins were stored in aliquots at 280uCu n t i lu s e [ 8 ] .
Surface plasmon resonance assay
To characterize Tat binding with heparin, kinetic properties
and competitive inhibition were examined using a surface plasmon
resonance assay (SPR, BIAcore X, Uppsala, Sweden). For this
purpose, heparin was immobilized to CM5 sensor chip according
to established method[33,34]. The immobilization procedure was
carried out at 25uC and at a constant flow rate of 5 ml/min in
HBS-EP (0.01 M HEPES, pH 7.4, 0.15 M NaCl, 3 mM EDTA,
and 0.005% polysorbate 20 [v/v]). To assess the real-time binding
capacity, 50 ml of GST-Tat or the relevant mutant was injected
over the sensor chip surface with the immobilized heparin,
followed by 5 min of washing with HBS-EP buffer. The sensor
chip surface was regenerated using 2 M NaCl. All binding
experiments were performed at 25uC with a constant flow rate
of 15 ml/min HBS-EP. To correct for nonspecific binding and
bulk refractive index change, a blank channel (FC2) without
heparin was employed as a control for each experiment.
Sensorgrams for all binding interactions were recorded in real
time and analyzed after subtraction of channel blanks. Changes in
mass due to the binding response were recorded as resonance units
(RU). Binding kinetics and affinities were calculated using BIAcore
software 3.1. Competitive inhibition experiments were conducted
with the same protocol except a 50 ml mixture of GST-Tat or the
relevant mutant and inhibitors that had been preincubated for
3 min at 37uC were used.
Internalization of GST-Tat and its mutants[10]
Three hundred microliter of SLK cell suspensions were seeded
on each cover slips(3610
5 cells/ml in RPMI1640 with 10% FCS).
After 12 h, GST-Tat or the relevant mutant protein (1.6 mg/ml)
was added to the cell culture medium and incubated for 24 h.
Cells were then washed three times with phosphate buffered saline
(PBS) and fixed with cold 4% (v/v) paraformaldehyde for 30 min
at room temperature. Subsequently, the cover slips were washed
with PBS, permeabilized for 15 min in PBS containing 0.1% (v/v)
Triton X-100, and blocked with 1.25% (w/v) heat-denatured BSA
for 30 min at room temperature. Cells were then incubated with
an anti-GST monoclonal antibody (sc-459; [1:100]) at 4uC
overnight, followed by incubation with FITC-conjugated goat
anti-rabbit IgG (1:500) at 37uC for another 30 min, and imaged
using immunofluorescence confocal microscopy (LSM510-Meta,
Carl Zeiss, Germany).
Cell adhesion assay
To guarantee the same amount of tested protein was coated,
anti-GST antibody was adsorbed to polystyrene microplates
(Costar, Cambridge, Mass.) by overnight incubation at 4uCi n
100 mM carbonate buffer (pH 9.6) at a concentration of 10 mg/
ml. The plates were subsequently washed three times with tris-
buffered saline+Tween 20 (TBS-T) and then filled with 1.25%
BSA-PBS and incubated for 2 h at 37uC. After three washes with
TBS-T, 40 mg/ml of GST alone, GST-Tat or the relevant mutant
Tat protein was added to the wells and incubated for 1 hour at
37uC. The plate was next washed three times with PBS-T. Then
100 ml of SLK cell suspension was added to each well
(3610
5 cells/ml in RPMI1640 with 10% FCS). After incubation
for 1 hour at 37uC in a 5% CO2 atmosphere, non-adherent cells
were removed by careful aspiration and three washes with
RPMI1640. Adherent cells were fixed, stained, and quantitated
as described[35]. A heparin competition cell adhesion assay was
conducted with the same procedure except that heparin at defined
Table 2. Summary of mutated amino acid of series GST-Tat
mutants.
Mutants name Amino acids change
GST-Tat(G48-R57)A amino acids 48–57( basic domain)RAla
GST-TatK(12,41)A/R78A Lys12, Lys41, Arg78RAla
GST-TatK12A Lys12RAla
GST-TatK41A Lys41RAla
GST-TatR78A Arg78RAla
GST-TatK(12,41)A Lys12, Lys41RAla
GST-TatK12A/R78A Lys12, Arg78RAla
GST-TatK41A/R78A Lys41, Arg78RAla
GST-TatR78A/G79A/D80A Arg78, Gly79, Asp80RAla
GST-Tat(G48-R57)A/K(12,41)A/R78A amino acids 48–57, Lys12, Lys41, and Arg78RAla
doi:10.1371/journal.pone.0002662.t002
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blocked cell adhesion assay, cell surface HS was blocked by
preincubation with function-blocking monoclonal antibody
(MAB2040) against cell membrane HS at 37uC for 1 hour before
being added to each well. Each experiment was performed in
triplicate and replicated three times.
Integrin clustering assay
The protein coating and cell treatment were similiar as the
procedure of cell adhesion except using acid-washed cover slips
instead of polystyrene microplates. The adherent cells were then
fixed in 4%(v/v) paraformaldehyde for 30 min, permeabilized
with 0.1%(v/v) Triton X-100 in PBS for 10 min at room
temperature, and treated with blocking buffer (1.25% (w/v) BSA
in PBS). Cells were then incubated with monoclonal anti-12G10
(1:100) directed against the activated-b1 integrin at 4uC overnight,
followed by incubation with Cy3-conjugated anti-mouse IgG
(1:1000) at 37uC for another 30 min and imaged using
immunofluorescence confocal microscopy. A heparin-saturation
integrin clustering assay was conducted using the same procedure
except that heparin (final concentration 1 mg/ml) was added to
the wells and incubated for 1 hour with GST, GST-Tat or the
appropriate mutant Tat protein before adding cells.
Supporting Information
Text S1 Supplementary Methods and Results
Found at: doi:10.1371/journal.pone.0002662.s001 (0.03 MB
DOC)
Figure S1 The representative MS-MS spectrum of GST-Tat. A,
The MS-MS spectrum of GST-Tat peptide, LEPWKHPGSQPK,
with Xcorr score 2.48; and B, The MS-MS spectrum of GST-Tat
peptide, RPPQGSQTHQVSLSK, with Xcorr score 4.03.
Found at: doi:10.1371/journal.pone.0002662.s002 (0.97 MB TIF)
Figure S2 The MS-MS spectrum of GST-Tat mutant GST-
Tat(G48-R57)A. The peptide ALGISYAAAAAAAAAAPPQGSQ
THQVSLSK, with Xcorr score of 5.62, indication of the 48–57
residues substituted by Alanine (The mutated amino acids are
underlined).
Found at: doi:10.1371/journal.pone.0002662.s003 (0.53 MB TIF)
Figure S3 The MS-MS spectrum of GST-Tat mutant GST-
TatK(12,41)A/R78A. A, The MS-MS spectrum of GST-
TatK(12,41)A/R78A peptide, LEPWAHPGSQPK, with Xcorr
score 2.78, indication of the twelfth residue Lysine of Tat
substituted by Alanine; B, The MS-MS spectrum of GST-
TatK(12,41)A/R78A peptide, CCFHCQVCFITAALGISYGR,
with Xcorr score 5.32, indication of the forty-first residue Lysine
of Tat substituted by Alanine; and C, The MS-MS spectrum of
GST-TatK(12,41)A/R78A peptide, QPTSQSAGDPTGPK, with
Xcorr score 2.8, indication of the seventy-eighth Arg of Tat
substituted by Alanine. The mutated amino acids are underlined.
Found at: doi:10.1371/journal.pone.0002662.s004 (1.65 MB TIF)
Figure S4 The MS-MS spectrum of GST-Tat mutant GST-
Tat(G48-R57)A/K(12,41)A/R78A. A, The MS-MS spectrum of
GST-Tat(G48-R57)A/K(12,41)A/R78A peptide, LEPWAHPGS
QPK, with Xcorr score 2.9, indication of the twelfth residue
Lysine of Tat substituted by Alanine; B, The MS-MS spectrum of
GST-Tat(G48-R57)A/K(12,41)A/R78A peptide, CCFHCQVC
FITAALGISYAAAAAAAAAAPPQGSQTHQVSLSK, with Xcorr
score 4.83, indication of the forty-first residue Lysine and the 48–57
residues of Tat substituted by Alanine; and C, The MS-MS
spectrum of GST-Tat(G48-R57)A/K(12,41)A/R78A peptide,
QPTSQSAGDPTGPKE, with Xcorr score 3.14, indication of the
seventy-eighth Arg of Tat substituted by Alanine. The mutated
amino acids are underlined.
Found at: doi:10.1371/journal.pone.0002662.s005 (1.67 MB TIF)
Author Contributions
Conceived and designed the experiments: MG XX. Performed the
experiments: JA XX. Analyzed the data: MG JA XX JL. Wrote the
paper: MG JA. Designed and exercised molecular docking: MZ HJ.
Performed and analyzed the MS-MS data: SW SP HJ. Constructed the
plasmid: LW HJ. Designed molecular docking and critical discussion: HJ.
References
1. Dewhurst S, Gelbard HA, Fine SM (1996) Neuropathogenesis of AIDS. Mol
Med Today 2: 16–23.
2. Noonan D, Albini A (2000) From the outside in: extracellular activities of HIV
Tat. Adv Pharmacol 48: 229–250.
3. Caputo A, Boarini BM, Mantovani I, Corallini A, Barbanti Brodano G (1999)
Multiple functions of human immunodeficiency virus type 1 Tat protein in the
pathogenesis of AIDS. Recent Res Dev Virol 1: 753–778.
4. Barillari G, Ensoli B (2002) Angiogenic effects of extracellular human
immunodeficiency virus type 1 Tat protein and its role in the pathogenesis of
AIDS-associated Kaposi’s sarcoma. Clin Microbiol Rev 15: 310–326.
5. Cullen BR (1990) The HIV-1 Tat protein: an RNA sequence-specific
processivity factor? Cell 63: 655–657.
6. Rusnati M, Presta M (2002) HIV-1 Tat protein and endothelium: from protein/
cell interaction to AIDS-associated pathologies. Angiogenesis 5: 141–151.
7. Ziegler A, Seelig J (2004) Interaction of the protein transduction domain of HIV-
1 TAT with heparan sulfate: binding mechanism and thermodynamic
parameters. Biophys J 86: 254–263.
8. Rusnati M, Coltrini D, Oreste P, Zoppetti G, Albini A, et al. (1997) Interaction
of HIV-1 Tat protein with heparin. Role of the backbone structure, sulfation,
and size. J Biol Chem 272: 11313–11320.
9. Rusnati M, Tulipano G, Urbinati C, Tanghetti E, Giuliani R, et al. (1998) The
basic domain in HIV-1 Tat protein as a target for polysulfonated heparin-
mimicking extracellular Tat antagonists. J Biol Chem 273: 16027–16037.
10. Tyagi M, Rusnati M, Presta M, Giacca M (2001) Internalization of HIV-1 tat
requires cell surface heparan sulfate proteoglycans. J Biol Chem 276:
3254–3261.
11. Fittipaldi A, Giacca M (2005) Transcellular protein transduction using the Tat
protein of HIV-1. Adv Drug Deliv Rev 57: 597–608.
12. Cole C, Barber JD, Barton GJ (2008) The Jpred 3 secondary structure prediction
server. Nucleic Acids Res.
13. Rusnati M, Tulipano G, Spillmann D, Tanghetti E, Oreste P, et al. (1999)
Multiple interactions of HIV-I Tat protein with size-defined heparin
oligosaccharides. J Biol Chem 274: 28198–28205.
14. Barillari G, Sgadari C, Fiorelli V, Samaniego F, Colombini S, et al. (1999) The
Tat protein of human immunodeficiency virus type-1 promotes vascular cell
growth and locomotion by engaging the alpha5beta1 and alphavbeta3
integrins and by mobilizing sequestered basic fibroblast growth factor. Blood
94: 663–672.
15. Fournier HN, Dupe-Manet S, Bouvard D, Lacombe ML, Marie C, et al. (2002)
Integrin cytoplasmic domain-associated protein 1alpha (ICAP-1alpha ) interacts
directly with the metastasis suppressor nm23-H2, and both proteins are targeted
to newly formed cell adhesion sites upon integrin engagement. J Biol Chem 277:
20895–20902.
16. Pankov R, Cukierman E, Clark K, Matsumoto K, Hahn C, et al. (2003) Specific
beta1 integrin site selectively regulates Akt/protein kinase B signaling via local
activation of protein phosphatase 2A. J Biol Chem 278: 18671–18681.
17. Thodeti CK, Albrechtsen R, Grauslund M, Asmar M, Larsson C, et al. (2003)
ADAM12/syndecan-4signalingpromotesbeta1integrin-dependentcellspreading
through protein kinase Calpha and RhoA. J Biol Chem 278: 9576–9584.
18. Bich C, Scott M, Panagiotidis A, Wenzel RJ, Nazabal A, et al. (2007)
Characterization of antibody-antigen interactions: Comparison between surface
plasmon resonance measurements and high-mass matrix-assisted laser desorp-
tion/ionization mass spectrometry. Anal Biochem.
19. Nguyen B, Tanious FA, Wilson WD (2007) Biosensor-surface plasmon
resonance: quantitative analysis of small molecule-nucleic acid interactions.
Methods 42: 150–161.
20. Pattnaik P (2005) Surface plasmon resonance: applications in understanding
receptor-ligand interaction. Appl Biochem Biotechnol 126: 79–92.
21. Mulloy B (2005) The specificity of interactions between proteins and sulfated
polysaccharides. An Acad Bras Cienc 77: 651–664.
A Novel Heparin Binding Site
PLoS ONE | www.plosone.org 10 July 2008 | Volume 3 | Issue 7 | e266222. Katsuraya K, Nakashima H, Yamamoto N, Uryu T (1999) Synthesis of sulfated
oligosaccharide glycosides having high anti-HIV activity and the relationship
between activity and chemical structure. Carbohydr Res 315: 234–242.
23. Capila I, Linhardt RJ (2002) Heparin-protein interactions. Angew Chem Int Ed
Engl 41: 391–412.
24. Hileman RE, Fromm JR, Weiler JM, Linhardt RJ (1998) Glycosaminoglycan-
protein interactions: definition of consensus sites in glycosaminoglycan binding
proteins. Bioessays 20: 156–167.
25. Munoz EM, Linhardt RJ (2004) Heparin-binding domains in vascular biology.
Arterioscler Thromb Vasc Biol 24: 1549–1557.
26. Peloponese JM Jr, Gregoire C, Opi S, Esquieu D, Sturgis J, et al. (2000) 1H-13C
nuclear magnetic resonance assignment and structural characterization of HIV-
1 Tat protein. C R Acad Sci III 323: 883–894.
27. Sali A (1995) Comparative protein modeling by satisfaction of spatial restraints.
Mol Med Today 1: 270–277.
28. Mulloy B, Forster MJ, Jones C, Davies DB (1993) N.m.r. and molecular-
modelling studies of the solution conformation of heparin. Biochem J 293 (Pt 3):
849–858.
29. Garrett M, Morris DSG, Robert SHalliday, RuthHuey, William EHart,
Richard KBelew, Arthur JOlson (1999) Automated docking using a Lamarckian
genetic algorithm and an empirical binding free energy function. J Comput
Chem 19: 1639–1662.
30. Huey R, Morris GM, Olson AJ, Goodsell DS (2007) A semiempirical free
energy force field with charge-based desolvation. J Comput Chem 28:
1145–1152.
31. Morris GM, Goodsell DS, Huey R, Olson AJ (1996) Distributed automated
docking of flexible ligands to proteins: parallel applications of AutoDock 2.4.
J Comput Aided Mol Des 10: 293–304.
32. Wallace AC, Laskowski RA, Thornton JM (1995) LIGPLOT: a program to
generate schematic diagrams of protein-ligand interactions. Protein Eng 8:
127–134.
33. Li FC QX, Geng MY (2003) A Novel Method of Immobilization of 911 for
Surface Plasmon Resonance Biosensor. Chinese J Anal Chem 31: 266–269.
34. Liu H, Geng M, Xin X, Li F, Zhang Z, et al. (2005) Multiple and multivalent
interactions of novel anti-AIDS drug candidates, sulfated polymannuronate
(SPMG)-derived oligosaccharides, with gp120 and their anti-HIV activities.
Glycobiology 15: 501–510.
35. Hutchings H, Ortega N, Plouet J (2003) Extracellular matrix-bound vascular
endothelial growth factor promotes endothelial cell adhesion, migration, and
survival through integrin ligation. Faseb J 17: 1520–1522.
A Novel Heparin Binding Site
PLoS ONE | www.plosone.org 11 July 2008 | Volume 3 | Issue 7 | e2662